The FDA last week approved GSK’s JAK inhibitor Ojjaara (momelotinib) for broad use in intermediate or high-risk myelofibrosis, a rare blood cancer, in patients with anemia. GSK says it is the only approved myelofibrosis therapy available for both newly diagnosed and previously treated patients “that addresses the key manifestations of the disease, namely anaemia, constitutional symptoms and splenomegaly (enlarged spleen).” While Ojjaara is only available to anemic patients, it will still present a challenge to Incyte’s JAK powerhouse Jakafi (ruxolitinib) in the myelofibrosis market basket. Under the pharmacy benefit, Jakafi holds covered or better status as a myelofibrosis therapy for virtually all insured lives. About 16% of lives have preferred access to Jakafi, growing to 34% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 9/18/23